01 4Kybella/Belkyra
Main Therapeutic Indication : Submental Fat
Currency : USD
2017 Revenue in Millions : 56
2016 Revenue in Millions : 53
Growth (%) : 7
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2018 Revenue in Millions : 38
2017 Revenue in Millions : 56
Growth (%) : -32%
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2019 Revenue in Millions : 31
2018 Revenue in Millions : 38
Growth (%) : -19
Main Therapeutic Indication : Submental Fat
Currency : USD
2016 Revenue in Millions : 53
2015 Revenue in Millions : 3
Growth (%) : 1,667
LOOKING FOR A SUPPLIER?